Cantor Fitzgerald Reiterates Overweight on Oncolytics Biotech
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Oncolytics Biotech, indicating a positive outlook for the company's stock.
September 20, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Louise Chen has reiterated an Overweight rating on Oncolytics Biotech, suggesting a positive outlook for the company's stock.
The reiteration of an Overweight rating by a reputable analyst like Louise Chen from Cantor Fitzgerald is likely to boost investor confidence in Oncolytics Biotech, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100